Merck & Co Inc. (MRK) on Friday said it has agreed to acquire CN201, an investigational bispecific antibody for the treatment of B-cell associated diseases from Curon Biopharmaceutical.
As per the deal, Merck, through a subsidiary will acquire global rights to CN201 for an upfront payment of $700 million in cash, and milestone payments of up to $600 million associated with the development and approval of CN201.
CN201 is currently being evaluated in a Phase 1 study in relapsed or refractory non-Hodgkin's lymphoma (NHL), and in a Phase 1b/2 study in relapsed or refractory B-cell acute lymphocytic leukemia (ALL)
The transaction is expected to close in the third quarter of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.